uniQure (NASDAQ:QURE) Receives $18.60 Consensus PT from Brokerages

Shares of uniQure (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.60.

QURE has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of uniQure in a research report on Tuesday, August 20th. StockNews.com upgraded uniQure to a “sell” rating in a report on Monday, August 5th. The Goldman Sachs Group upped their target price on uniQure from $6.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price target on shares of uniQure in a research note on Tuesday, July 16th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in uniQure by 173.5% during the fourth quarter. BNP Paribas Financial Markets now owns 706,670 shares of the biotechnology company’s stock valued at $4,784,000 after purchasing an additional 448,319 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at about $86,000. Sectoral Asset Management Inc. bought a new stake in shares of uniQure in the 4th quarter valued at about $1,981,000. Vestal Point Capital LP purchased a new position in shares of uniQure in the 4th quarter worth approximately $26,572,000. Finally, Pale Fire Capital SE raised its stake in shares of uniQure by 9.2% during the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 5,500 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Stock Up 1.3 %

uniQure stock opened at $5.54 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.36 and a quick ratio of 7.36. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company’s 50-day moving average is $6.93 and its 200 day moving average is $5.65.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.08. uniQure had a negative return on equity of 158.09% and a negative net margin of 1,027.52%. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $3.47 million. Equities research analysts anticipate that uniQure will post -4.04 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.